GSK adds liver candidate from Wave RNA partnership

Why it matters: The decision shows that the companies’ RNA drug discovery alliance continues to deliver candidates, despite GSK relinquishing rights to Wave’s lead RNA editing therapy earlier this year. It also adds to GSK’s work in liver disease, where its own small interfering RNA (siRNA) candidate gatuzosiran is already in Phase 2 development.

Highlight Therapeutics’ skin cancer injections show promise in Phase 2b

Why it matters: Highlight is developing the injected immunotherapy as a potential alternative to surgery, particularly for tumors on the face and neck. Surgery remains the most common treatment, but removing tumors in these sensitive areas can leave scars and require reconstruction.

September in review: BASF eyes Evonik, EU Green Transition Directive, GLP-1 and beauty

In September, BASF confirmed takeover talks with Evonik, a deal that could consolidate two of Europe’s largest beauty suppliers. 

Boehringer, Zealand obesity drug face tolerability questions after Phase 3 success

Why it matters: The results strengthen the evidence for the Zealand Pharma-originated drug in a population where weight loss is typically harder to achieve. However, its efficacy faces strong competition from existing treatments, while the discontinuation rate raises questions about how many patients could sustain treatment.

Abolis turns microbial data into faster beauty R&D with MINE

Abolis Biotechnologies has launched Microbial Intelligence Explorer (MINE), a platform that helps cosmetics players understand, interpret, and act on complex biological data for easier decision-making in the cosmetics pipeline. 

Sanofi pays $1B upfront to expand Regeneron alliance beyond Dupixent

Why it matters: The companies are building on the inflammatory pathways behind one of biopharma’s biggest commercial successes. Longer-acting treatments could reduce the injection burden for patients, although the new candidates remain early in development.

Atrogi’s muscle drug shows early power signal ahead of Phase 2

Why it matters: Developers of weight-loss treatments are looking for ways to preserve lean mass as people lose fat. Despite being early, Atrogi’s results raise the possibility that ATR-258 could improve muscle performance during weight-loss treatment or in conditions affecting muscle function.

Vigiagro intercepta praga quarentenária em carga de caquis

Servidores da Vigilância Agropecuária Internacional (Vigiagro) interceptaram a praga quarentenária ausente Liposcelis de…

Lagartas terrestres exibem diferentes formas de nado

doi 10.1093/jisesa/ieag100 Lagartas terrestres de diferentes grupos de Lepidoptera conseguem executar movimentos coorden…

Efetores LysM favorecem colonização de trigo por Sclerotinia

doi 10.1111/mpp.70355 Duas proteínas efetoras de Sclerotinia sclerotiorum favorecem a colonização endofítica do trigo po…